Nuvalent Inc (NUVL)
Healthcare
Biotechnology
124.00 $
+0.0%
vs. previous close
Closing price · As of: 21. Jul 2026
Who owns Nuvalent Inc (NUVL)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 66.5% of the shares are freely tradable; institutional investors hold 113.1%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
113.1%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
2.8%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
66.5%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
6.6%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
74Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Deerfield Management Co | 22.05 | 17,248,450 | +0.0 | 03/31/2026 |
| FMR Inc | 11.85 | 9,274,959 | -14.5 | 03/31/2026 |
| Paradigm Biocapital Advisors LP | 6.81 | 5,324,433 | +1.0 | 03/31/2026 |
| Vanguard Group Inc | 6.70 | 5,244,271 | +13.9 | 12/31/2025 |
| BlackRock Inc | 6.17 | 4,824,785 | +0.4 | 03/31/2026 |
| JPMorgan Chase & Co | 3.95 | 3,088,349 | +40.0 | 03/31/2026 |
| RA Capital Management, LLC | 3.24 | 2,534,145 | +34.8 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 3.20 | 2,500,907 | +0.0 | 03/31/2026 |
| Wellington Management Company LLP | 3.16 | 2,470,491 | +0.4 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.10 | 2,428,488 | +0.0 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 15. Jul 2026 | Flynn James E | Director | Other | 3,444 | 124.00 | 427,056 |
| 15. Jul 2026 | Flynn James E | Director | Other | 5,146 | 124.00 | 638,104 |
| 15. Jul 2026 | Flynn James E | Director | Other | 650,000 | 124.00 | 80,600,000 |
| 15. Jul 2026 | Flynn James E | Director | Other | 8,299,225 | 124.00 | 1,029,103,900 |
| 15. Jul 2026 | Meyers Michael L. | Director | Other | 3,444 | – | – |
| 15. Jul 2026 | Meyers Michael L. | Director | Other | 5,146 | 124.00 | 638,104 |
| 15. Jul 2026 | Balcom Alexandra | Chief Financial Officer | Other | 14,350 | – | – |
| 15. Jul 2026 | Balcom Alexandra | Chief Financial Officer | Other | 14,350 | 0.00 | – |
| 15. Jul 2026 | Balcom Alexandra | Chief Financial Officer | Other | 41,100 | – | – |
| 15. Jul 2026 | Balcom Alexandra | Chief Financial Officer | Other | 44,433 | 124.00 | 5,509,692 |
| 15. Jul 2026 | Srivastava Sapna | Director | Other | 3,444 | – | – |
| 15. Jul 2026 | Srivastava Sapna | Director | Other | 5,146 | 124.00 | 638,104 |
| 15. Jul 2026 | Oliger Christy J. | Director | Other | 6,091 | – | – |
| 15. Jul 2026 | Oliger Christy J. | Director | Other | 1,324 | 124.00 | 164,176 |
| 15. Jul 2026 | Squarer Ron | Director | Other | 6,281 | – | – |
| 15. Jul 2026 | Turner Christopher Durant | Chief Medical Officer | Other | 14,350 | – | – |
| 15. Jul 2026 | Turner Christopher Durant | Chief Medical Officer | Other | 14,350 | 0.00 | – |
| 15. Jul 2026 | Turner Christopher Durant | Chief Medical Officer | Other | 41,100 | – | – |
| 15. Jul 2026 | Turner Christopher Durant | Chief Medical Officer | Other | 31,530 | 124.00 | 3,909,720 |
| 15. Jul 2026 | Noci Darlene | Chief Development Officer | Other | 14,350 | – | – |
| 15. Jul 2026 | Noci Darlene | Chief Development Officer | Other | 14,350 | 0.00 | – |
| 15. Jul 2026 | Noci Darlene | Chief Development Officer | Other | 41,100 | – | – |
| 15. Jul 2026 | Noci Darlene | Chief Development Officer | Other | 17,017 | 124.00 | 2,110,108 |
| 15. Jul 2026 | Lane Benjamin | See Remarks | Other | 7,120 | – | – |
| 15. Jul 2026 | Lane Benjamin | See Remarks | Other | 7,120 | 0.00 | – |
| 15. Jul 2026 | Lane Benjamin | See Remarks | Other | 29,433 | – | – |
| 15. Jul 2026 | Lane Benjamin | See Remarks | Other | 21,092 | 124.00 | 2,615,408 |
| 15. Jul 2026 | Pelish Henry E. | Chief Scientific Officer | Other | 14,350 | – | – |
| 15. Jul 2026 | Pelish Henry E. | Chief Scientific Officer | Other | 14,350 | 0.00 | – |
| 15. Jul 2026 | Pelish Henry E. | Chief Scientific Officer | Other | 41,100 | – | – |
| 15. Jul 2026 | Pelish Henry E. | Chief Scientific Officer | Other | 22,393 | 124.00 | 2,776,732 |
| 15. Jul 2026 | Porter James Richard | President and CEO | Other | 40,025 | – | – |
| 15. Jul 2026 | Porter James Richard | President and CEO | Other | 40,025 | 0.00 | – |
| 15. Jul 2026 | Porter James Richard | President and CEO | Other | 121,350 | – | – |
| 15. Jul 2026 | Porter James Richard | President and CEO | Other | 203,529 | 124.00 | 25,237,596 |
| 15. Jul 2026 | Miller Deborah Ann | Chief Legal Officer | Other | 14,350 | – | – |
| 15. Jul 2026 | Miller Deborah Ann | Chief Legal Officer | Other | 14,350 | 0.00 | – |
| 15. Jul 2026 | Miller Deborah Ann | Chief Legal Officer | Other | 41,100 | – | – |
| 15. Jul 2026 | Miller Deborah Ann | Chief Legal Officer | Other | 18,534 | 124.00 | 2,298,216 |
| 15. Jul 2026 | Protopapas Anna | Director | Other | 3,444 | – | – |
| 15. Jul 2026 | Protopapas Anna | Director | Other | 5,146 | 124.00 | 638,104 |
| 15. Jul 2026 | Bogle Grant C. | Director | Other | 5,577 | – | – |
| 15. Jul 2026 | Bogle Grant C. | Director | Other | 3,714 | 124.00 | 460,536 |
| 15. Jul 2026 | Wheeler Cameron | Director | Other | 3,444 | – | – |
| 15. Jul 2026 | Wheeler Cameron | Director | Other | 5,146 | 124.00 | 638,104 |
| 6. Jul 2026 | Porter James Richard | President and CEO | Sell | 30,000 | 123.72 | 3,711,600 |
| 6. Jul 2026 | Porter James Richard | President and CEO | Other | 30,000 | 18.93 | 567,900 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Data as of: July 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.